Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to “Sell” by StockNews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by equities researchers at StockNews.com to a “sell” rating in a report issued on Wednesday.

A number of other brokerages also recently issued reports on LXRX. SVB Leerink began coverage on Lexicon Pharmaceuticals in a research report on Tuesday. They set an “outperform” rating and a $5.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 23rd.

Lexicon Pharmaceuticals Trading Down 1.3 %

LXRX stock opened at $1.54 on Wednesday. The firm has a market cap of $379.21 million, a PE ratio of -1.92 and a beta of 1.27. The firm has a fifty day moving average price of $2.15 and a 200 day moving average price of $1.74. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.58 and a current ratio of 5.60. Lexicon Pharmaceuticals has a fifty-two week low of $0.92 and a fifty-two week high of $3.79.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. Sell-side analysts anticipate that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BVF Inc. IL grew its stake in shares of Lexicon Pharmaceuticals by 22.2% during the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock valued at $37,387,000 after buying an additional 4,440,300 shares during the last quarter. SG Americas Securities LLC bought a new position in Lexicon Pharmaceuticals in the 3rd quarter valued at $64,000. KWB Wealth purchased a new stake in Lexicon Pharmaceuticals in the fourth quarter worth $62,000. RPO LLC bought a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth $49,000. Finally, TIAA Trust National Association purchased a new stake in shares of Lexicon Pharmaceuticals during the third quarter valued at $29,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.